UnitedHealth Says Aduhelm Coverage Decision Will Hinge on Medicare Guidance

During the company’s July 15 call to discuss second-quarter 2021 financial results, UnitedHealth Group executives — perhaps unsurprisingly — fielded a question about how the company is approaching Aduhelm (aducanumab), the pricey new Alzheimer’s disease therapy that continues to be shrouded in controversy.

Chief Medical Officer Richard Migliori, M.D., told analysts that “we are continuing to develop our clinical policy as well as our ultimate position on coverage, but in doing so we’re looking forward to getting the guidance that we need from Medicare.” CMS on July 12 said it was opening a National Coverage Determination analysis on Aduhelm, which will ultimately specify how Medicare will cover the $56,000 per year treatment. In the meantime, coverage will be determined at a local level by Medicare Administrative Contractors, the Biden administration said.

0 Comments
© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

cms-website
February 23

Panelists: CMS Prior Authorization Rule Should Help, But More Is Needed

READ MORE
blue-cross-blue-shield-image
February 23

Checking on the Blues: Analysts Predict Margin Uptick in ’23 Will Be Short-Lived

READ MORE
techy-illustration
February 23

ONC Head Touts Interoperability Wins, Poses AI Questions

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today